grant
Elucidating Treg defects in ALS
Organization BRIGHAM AND WOMEN'S HOSPITALLocation BOSTON, UNITED STATESPosted 6 Feb 2026Deadline 31 Jan 2031
NIHUS FederalResearch GrantFY20260-11 years oldALS patientsALS therapyALS treatmentAdoptive Cell TransfersAdoptive TransferAffectAmyotrophic Lateral Sclerosis patientsAutomobile DrivingAutoregulationBasal Transcription FactorBasal transcription factor genesBloodBlood Reticuloendothelial SystemBlood monocyteCD3CD3 AntigensCD3 ComplexCD3 moleculeCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCausalityCell BodyCell DeathCell FunctionCell LineageCell PhysiologyCell ProcessCellsCellular FunctionCellular PhysiologyCellular ProcessChildChild YouthChildren (0-21)Clinical TrialsCo-StimulatorCo-cultureCocultivationCocultureCoculture TechniquesCollaborationsCostimulatorDNA mutationDataDefectDegenerative Neurologic DisordersDiagnosisDiseaseDisease ProgressionDisorderDoseDysfunctionEarly-Stage Clinical TrialsEnvironmentEpidermal Thymocyte Activating FactorEtiologyEventExhibitsFOXP3FOXP3 geneForkhead Box P3FrequenciesFunctional disorderGene ExpressionGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGeneralized GrowthGenesGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGoalsGrowthHematopoieticHomeostasisHortega cellHumanIL-2IL2 ProteinIPEXImmuneImmune Cell ActivationImmune systemImmunesImmunodysregulation polyendocrinopathy enteropathy X-linked syndromeImpairmentIn VitroInflammationInterleukin 2Interleukin 2 PrecursorInterleukin IIInterleukin-2Interleukine 2Interleukine 2 PrecursorInterleukine IIJM2Lymphocyte Mitogenic FactorMarrow monocyteMeasuresMemoryMethodsMicrogliaMitogenic FactorModern ManMotor CellMotor NeuronsMutationMyelogenousMyeloidNervous System Degenerative DiseasesNeural Degenerative DiseasesNeural degenerative DisordersNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNeuronal DysfunctionOKT3 antigenOxidative StressPBMCPathologyPathway interactionsPatientsPeripheral Blood Mononuclear CellPhase 1 Clinical TrialsPhase I Clinical TrialsPhysiological HomeostasisPhysiopathologyPlayPopulationProcessRNA ExpressionRNA ProcessingRegulationRegulatory T-LymphocyteResistanceRestRoleSCURFINSpecificitySubcellular ProcessT cell growth factorT-Cell Growth FactorT-Cell Stimulating FactorT-CellsT-LymphocyteT3 AntigensT3 ComplexT3 moleculeT4 CellsT4 LymphocytesTestingTherapeuticTherapeutic InterventionTherapy Clinical TrialsTherapy trialThymocyte Stimulating FactorTimeTissue GrowthTranscriptionTranscription Factor Proto-OncogeneTranscription factor genesTregWorkaberrant protein foldingabnormal protein foldingadoptive cell therapyadoptive cellular therapyadvanced diseaseadvanced illnessamyotrophic lateral sclerosis therapyamyotrophic lateral sclerosis treatmentcausationdegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdisease causationdrivingefficacious therapyefficacious treatmentfitnessgenome mutationgitter cellhemopoieticimmune activationin vivoinsoluble aggregateintervention therapykidsloss of functionmesogliamicroglial cellmicrogliocytemitochondrial dysfunctionmonocytemotoneuronmotor neuron degenerationmouse modelmurine modelnecrocytosisnerve cell deathnerve cell lossneural dysfunctionneural inflammationneurodegenerative illnessneuroinflammationneuroinflammatoryneuron cell deathneuron cell lossneuron deathneuron lossneuronal cell deathneuronal cell lossneuronal deathneuronal lossontogenypathologic protein foldingpathophysiologypathwayperivascular glial cellphase I protocolproliferation capabilityproliferation capacityproliferation potentialproliferative capabilityproliferative capacityproliferative potentialprotein aggregateprotein aggregationprotein misfoldingregulatory T-cellsresistantsocial roletherapeutic targetthymus derived lymphocytetissue repairtranscription factoryoungster
Description preview
1 There is a significant unmet need to identify disease ameliorating therapies for the treatment of ALS. It is
2 increasingly recognized that neuroinflammation plays a central role in driving the ALS progression. Regulatory
3 T cells (Tregs) are a lineage of CD4 T cells that regulate homeostasis by inhibiting inflammation and dampening
4 innate…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click